Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 73.4%

Neg 0% Neu 73.4% Pos 0%

Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.